Glutamate Carboxypeptidase-II (GCPII), also known as prostate-specific membrane antigen (PSMA), could be an important biomarker of aggressiveness, given that it has been reported to be expressed in BC tumor cells and even more in endothelial cells of tumor vessels. The gene discussed is FOLH1; the disease is breast cancer.